Black Friday Code: DIGEST35

What Is MCAS? Mast Cell Activation Syndrome Explained

Mast Cell Activation Syndrome (MCAS) causes allergy-like flares across the skin, gut, heart, and brain. Learn what MCAS is, its symptoms, causes, diagnosis, and treatment options.

Key Takeaways:
  • MCAS occurs when mast cells become overly reactive and release inflammatory chemicals too easily or too frequently.
  • Symptoms can migrate across body systems (skin, gut, brain, heart, lungs) and vary unpredictably from one episode to the next.
  • Common triggers include stress, certain foods, alcohol, strong odors, temperature changes, infections, and specific medications.
  • Gut health is a critical driver: IBS is 16 times more common in people with MCAS, and SIBO may be three times more prevalent. Improving the gut is often the most impactful first step.
  • Diagnosis requires recurring multisystem symptoms, measurable mast cell mediators, and a clear response to mast-cell-targeted therapies.
  • Treatment typically focuses on reducing triggers, improving gut health, stabilizing mast cells, and lowering overall inflammatory burden.

If you’ve ever felt like your body suddenly became reactive to everything—foods, stress, supplements, medications, temperature changes, and fragrances—it can be difficult to know where to begin.

One day, you develop flushing and dizziness after meals. Another day, abdominal cramping or hives seem to appear out of nowhere. Stress triggers heart palpitations. A strong perfume gives you a headache and brain fog. Standard testing comes back “normal,” but you still don’t feel well.

In some cases, this pattern may involve mast cell activation syndrome (MCAS), a condition in which immune cells called mast cells become overly sensitive and inappropriately or excessively release inflammatory chemicals.

MCAS is both increasingly recognized and frequently misunderstood, particularly online, where broad symptom patterns are sometimes attributed to mast cell disease without adequate evaluation.

In this article, I’ll walk through what MCAS is, how it’s diagnosed, conditions that can mimic it, and the treatment strategies I’ve found most clinically helpful, especially the role of gut health and immune regulation.

What Is Mast Cell Activation Syndrome?

Mast cell activation syndrome is a condition that causes unexplained, often severe symptoms due to overactive mast cells 1. Mast cells are immune cells found throughout the body, especially in tissues that interact with the outside world, including the skin, lungs, digestive tract, and blood vessels.

Their job is protective. When mast cells detect a potential threat such as an allergen, infection, toxin, or injury, they release inflammatory compounds including histamine, tryptase, leukotrienes, prostaglandins, and cytokines. These compounds help coordinate immune defense and healing.

In MCAS, mast cells become unusually reactive. Instead of responding appropriately to genuine threats, they may release inflammatory mediators too easily, too frequently, or in response to otherwise harmless stimuli 1.

Common triggers include 2

  • Stress
  • Certain foods (especially high-histamine foods)
  • Alcohol (including alcohol in hand sanitizers and herbal medications)
  • Strong odors (perfumes, smoke, cleaning products)
  • Large temperature fluctuations
  • Infections and toxins
  • Certain medications (NSAIDs, antibiotics, morphine, aspirin)
  • Exercise
  • Irritation from clothing (such as clothes that are too tight or itchy fabric)
  • Bug bites or allergic reactions
  • Additives in medications (colorants, preservatives, fillers)

The result may be recurring, multisystem symptoms mimicking severe allergic reactions, often with no identifiable allergen. And unlike a classic allergy, these symptoms move around the body, vary in intensity, and may affect multiple organ systems simultaneously 1.

MCAS Symptoms

Because mast cells exist throughout the body, symptoms can affect multiple organ systems simultaneously 3. MCAS symptoms are often less defined by any single symptom and more by the pattern: symptoms that fluctuate, affect two or more body systems, and seem disproportionately reactive to everyday exposures 3.

What Is MCAS? Mast Cell Activation Syndrome Explained -

MCAS can also cause anaphylaxis, a severe and potentially life-threatening medical emergency 3. One of the confusing aspects of MCAS is that symptoms may fluctuate significantly over time. A person may primarily experience digestive symptoms during one flare and neurological or skin symptoms during another.

Importantly, symptoms alone are not enough to diagnose MCAS. Many chronic inflammatory, gastrointestinal, neurological, and autonomic conditions can produce overlapping symptom patterns.

In fact, one study evaluating 100 patients with suspected MCAS found that only a small minority ultimately met full diagnostic criteria after comprehensive evaluation 4. This is why a careful diagnostic process matters.

Is It MCAS or Something Else?

Before pursuing an MCAS diagnosis, it’s important to consider conditions that look very similar, either because they share symptoms or because they can coexist with (and contribute to) MCAS.

Conditions that can mimic MCAS include: 

  • Histamine intolerance: Occurs when the body cannot adequately break down histamine, often due to reduced diamine oxidase (DAO) activity or excessive dietary histamine intake. Symptoms can overlap heavily with MCAS, especially flushing, headaches, gastrointestinal symptoms, and food reactions. However, histamine intolerance is not the same as MCAS 5.
  • Inflammatory bowel disease (IBD) and celiac disease: Produce gut-driven inflammation that can mimic the gastrointestinal (GI) symptoms of MCAS 5.
  • SIBO (small intestinal bacterial overgrowth): SIBO appears strongly associated with mast cell activation. Excess bacterial fermentation in the small intestine may increase immune activation, intestinal permeability, and histamine-related symptoms. Clinically, I often see significant symptom improvement when gut dysfunction is addressed, even in patients who never receive a formal MCAS diagnosis 6.
  • Fibromyalgia and chronic fatigue syndrome: Share significant symptom overlap, particularly around pain, brain fog, and fatigue 5.
  • Panic disorder: Cardiovascular and neurological symptoms of MCAS (racing heart, dizziness, sense of impending doom) can be mistaken for anxiety or panic attacks.
  • Systemic mastocytosis: A rare condition in which too many mast cells accumulate in the skin, bone marrow, or other organs. Symptoms can look identical to MCAS but may lead to organ damage if untreated 7

When clients come to me with suspected MCAS or MCAS-like symptoms, I follow a stepwise approach before pursuing a formal diagnosis:

  1. Improve gut health and reduce dietary histamine as a first intervention.
  2. If symptoms persist, I experiment with natural antihistamine therapies: probiotics, vitamin C, and quercetin.
  3. If symptoms continue, I have them complete an MCAS questionnaire based on the Afrin-Molderings assessment tool 8
  4. If they score above 8, I refer to an MCAS specialist for formal evaluation.

This approach is practical and productive: Many people find significant relief from gut health improvements and natural antihistamines regardless of whether they ultimately receive an MCAS diagnosis.

How Is MCAS Diagnosed?

According to consensus criteria, an MCAS diagnosis requires all three of the following 9

1. Recurring multisystem symptoms: Periodic episodes affecting at least two organ systems simultaneously, consistent with mast cell mediator release.

2. Measurable mediator evidence:  A rise in serum tryptase during a flare is the preferred marker. If tryptase testing is unavailable or inconclusive, urinary mast cell mediators such as histamine metabolites or prostaglandin D2 metabolites may also support the diagnosis.

3. Response to mast-cell-targeted treatment: Patients should demonstrate meaningful improvement with therapies aimed at stabilizing mast cells or blocking inflammatory mediators. Examples include:

  • H1 antihistamines
  • H2 blockers
  • Mast cell stabilizers
  • Leukotriene inhibitors

Not sure whether your symptoms point to MCAS? A helpful first step before seeking specialist testing is to take our MCAS Symptom Questionnaire, based on the validated Afrin-Molderings diagnostic framework 8. Scoring above 8 is a strong indicator to pursue specialist evaluation.

If you do pursue formal testing, working with an allergist or immunologist with MCAS experience is important. MCAS is currently both over- and underdiagnosed, depending on the clinical setting 10.

The Gut-MCAS Connection

One of the most clinically important aspects of MCAS is its relationship with gut health 11.

The gastrointestinal tract contains large numbers of mast cells, and disruptions in the gut microbiome may contribute to immune dysregulation and increased inflammatory signaling.

Research has found:

  • IBS is significantly more common in people with mast cell disorders. One study of 53 million patients found that people with IBS were 16 times more likely to have MCAS than those without IBS 12 
  • SIBO appears more prevalent in patients with MCAS 6
  • Intestinal hyperpermeability and microbial imbalance may contribute to mast cell activation
WHAT THE RESEARCH SHOWS
SIBO is three times more common in people with MCAS than in healthy people. And IBS, the most common functional gut disorder, is associated with a 16-times greater risk of MCAS. When there’s too much bacteria in the small intestine, the byproducts of fermentation can trigger immune reactivity and increase mast cell firing. Treating the gut often calms the whole system. (Weinstock et al., 2019; Kurin et al., 2022)

Clinically, improving gut health is often one of the highest-yield interventions.

Rather than immediately escalating to aggressive immune therapies, I typically begin with foundational interventions to reduce inflammatory load and improve gut function.

MCAS Treatment: A Step-by-Step Overview

Whether or not you have a formal diagnosis, the treatment approach is largely the same: reduce triggers, heal the gut, stabilize mast cells, and address underlying contributors. Here’s how I work through this with patients.

Step 1: Identify and Reduce Triggers

The first step is identifying patterns. Track your flares, what you ate, your stress levels, your environment, and timing to identify personal patterns. 

Reducing known triggers (high-histamine foods, alcohol, fragrances, temperature shifts, certain medications, stress) is one of the highest-impact steps available 13

Step 2: Improve Gut Health

The gut-MCAS relationship is bidirectional and clinically significant. IBS is associated with a 16x greater risk of MCAS (12), and SIBO may be 3x more prevalent in MCAS patients than in healthy people 6. Treating the gut through dietary changes, probiotics, and treating SIBO where present often produces broader symptom relief than adding another antihistamine.

From a dietary standpoint, a nutrient-rich, whole-foods diet is the starting point. A low-FODMAP diet works well when IBS symptoms predominate; a low-histamine diet when reactions are clearly food-driven 5. Probiotics can be a helpful strategy, although they haven’t yet been studied specifically for MCAS. But the adjacent research is promising. In the clinic, we see probiotics help histamine intolerance, and there is strong evidence showing that probiotics help with allergies 14

Step 3: Natural Antihistamine Support

Certain nutrients and compounds may help support mast cell regulation and histamine balance, including 15

  • Vitamin C
  • Quercetin 
  • Curcumin 
  • Omega-3 fatty acids
  • Vitamin D

Step 4: Prescription Medications

For confirmed MCAS with persistent symptoms, a specialist may recommend mast cell stabilizers (cromolyn sodium, ketotifen), H1 antihistamines (loratidine, cetirizine, fexofenadine), H2 antihistamines (famotidine), leukotriene inhibitors (montelukast), or anti-IgE medications (omalizumab). People with MCAS should consider carrying epinephrine auto-injectors 16

An Emerging Option: GLP-1 Receptor Agonists

One of the newer areas of interest in MCAS research involves GLP-1 receptor agonists (GLP-1RAs), medications originally developed for diabetes and weight management.

Researchers have become interested in these medications because mast cells appear to express GLP-1 receptors, raising the possibility that GLP-1 signaling may influence inflammatory pathways involved in mast cell activation.

WHAT THE RESEARCH SHOWS
A landmark 2025 case series published in The American Journal of the Medical Sciences followed 47 patients with treatment-resistant MCAS. Among them, 89% experienced clinical benefit with GLP-1 receptor agonists, often within hours to days, across inflammatory, neurologic, gastrointestinal, and autonomic symptoms. The authors called for rigorous clinical trials to define their role. (Afrin et al., Am J Med Sci, 2025)

This is early but compelling evidence. Microdosed GLP-1 formulations are now available through KoraMD, designed to harness the anti-inflammatory benefits at lower doses than those used for weight management. If you’re interested in exploring whether this is a fit, we can discuss it as part of your care plan.

Wondering where to start?

If you haven’t already, our MCAS Questionnaire is a great first step to assess whether your symptoms align with mast cell activation syndrome. Download the MCAS Questionnaire.

Mast Cell Activation Syndrome FAQs

What are the most common symptoms of MCAS?

MCAS most commonly causes skin symptoms (hives, flushing, itching), gastrointestinal symptoms (nausea, diarrhea, cramping, bloating), and cardiovascular symptoms (heart palpitations, dizziness, POTS-like symptoms). Brain fog, fatigue, headaches, and sensory neuropathy are also frequent. By definition, MCAS episodes should affect at least two organ systems simultaneously.

What is the life expectancy of someone with MCAS?

For most people, normal. The main serious risk is anaphylaxis, but death from anaphylaxis remains rare with proper management. With a personalized treatment plan and access to emergency medication (epinephrine), the vast majority of people with MCAS live full, active lives 17

What is the root cause of MCAS?

There’s no single root cause. MCAS involves a “bucket” of contributing factors: genetic predisposition (including KIT gene mutations), gut dysfunction (SIBO, dysbiosis, leaky gut), environmental exposures (mold, toxins, chemicals), chronic infections, hormonal fluctuations, and chronic stress. Effective treatment addresses multiple factors simultaneously rather than targeting a single cause in isolation.

What does mild MCAS look like?

Mild MCAS may present as low-grade, recurring symptoms that are easy to dismiss: occasional flushing, intermittent hives, frequent headaches, loose stools, or persistent fatigue that doesn’t respond to standard treatment. A person with mild MCAS may not have dramatic anaphylactic events, just a body that seems to overreact to food, stress, and environment in ways that feel disproportionate and unexplainable.

How is histamine intolerance different from MCAS?

In histamine intolerance, symptoms arise when the body can’t break down histamine properly, typically due to low diamine oxidase (DAO) enzyme activity or too many high-histamine foods. In MCAS, mast cells release far more than just histamine; they release dozens of mediators. The two conditions can coexist, and histamine intolerance can worsen MCAS symptoms. A low-histamine diet can help with both.

Bottom Line

MCAS is a complex but increasingly understood condition in which overactive mast cells produce allergy-like reactions across multiple body systems, often with no obvious trigger and no clear answer from conventional testing.

Whether or not you have a confirmed diagnosis, the treatment approach is the same: identify your triggers, improve your gut health, support your immune system with evidence-informed therapies, and work with a knowledgeable clinician who can tailor a plan to your specific picture. For many patients, gut-focused treatment alone, addressing SIBO, dysbiosis, and histamine load, produces remarkable improvement.

And for those who haven’t responded to standard care, emerging options like microdosed GLP-1 therapy offer new hope, based on promising early research.

If you’re struggling to get answers, we’re here to help. Learn more about how to become a patient at the Ruscio Institute for Functional Medicine, and let’s figure this out together.

➕ References

  1. Akin C. Dilemma of mast cell activation syndrome: overdiagnosed or underdiagnosed? J Allergy Clin Immunol Pract. 2024 Mar;12(3):762–3. DOI: 10.1016/j.jaip.2024.01.013. PMID: 38458701.
  2. Jennings SV, Slee VM, Finnerty CC, Hempstead JB, Bowman AS. Symptoms of mast cell activation: The patient perspective. Ann Allergy Asthma Immunol. 2021 Oct;127(4):407–9. DOI: 10.1016/j.anai.2021.07.004. PMID: 34271184.
  3. Castells M, Giannetti MP, Hamilton MJ, Novak P, Pozdnyakova O, Nicoloro-SantaBarbara J, et al. Mast cell activation syndrome: Current understanding and research needs. J Allergy Clin Immunol. 2024 Aug;154(2):255–63. DOI: 10.1016/j.jaci.2024.05.025. PMID: 38851398. PMCID: PMC11881543.
  4. Buttgereit T, Gu S, Carneiro-Leão L, Gutsche A, Maurer M, Siebenhaar F. Idiopathic mast cell activation syndrome is more often suspected than diagnosed-A prospective real-life study. Allergy. 2022 Sep;77(9):2794–802. DOI: 10.1111/all.15304. PMID: 35364617.
  5. Hamilton MJ, Scarlata K. Mast Cell Activation Syndrome: What it Is and Isn’t. Pract Gastroenterol. 2020 Jun; https://med.virginia.edu/ginutrition/wp-content/uploads/sites/199/2020/06/Mast-Cell-Activation-Syndrome-June-2020.pdf
  6. Weinstock LB, Brook J, Kaleem Z, Afrin L, Molderings G. 1194 small intestinal bacterial overgrowth is common in mast cell activation syndrome. Am J Gastroenterol. 2019 Oct;114(1):S671–S671. DOI: 10.14309/01.ajg.0000594304.61014.c5.
  7. Pardanani A. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management. Am J Hematol. 2019 Mar;94(3):363–77. DOI: 10.1002/ajh.25371. PMID: 30536695.
  8. Afrin LB, Molderings GJ. A concise, practical guide to diagnostic assessment for mast cell activation disease. World Journal of Hematology. 2014 Feb 6; https://www.wjgnet.com/2218-6204/full/v3/i1/1.htm
  9. Valent P, Hartmann K, Bonadonna P, Gülen T, Brockow K, Alvarez-Twose I, et al. Global Classification of Mast Cell Activation Disorders: An ICD-10-CM-Adjusted Proposal of the ECNM-AIM Consortium. J Allergy Clin Immunol Pract. 2022 Aug;10(8):1941–50. DOI: 10.1016/j.jaip.2022.05.007. PMID: 35623575.
  10. Zaghmout T, Maclachlan L, Bedi N, Gülen T. Low prevalence of idiopathic mast cell activation syndrome among 703 patients with suspected mast cell disorders. J Allergy Clin Immunol Pract. 2024 Mar;12(3):753–61. DOI: 10.1016/j.jaip.2023.11.041. PMID: 38056692.
  11. Weinstock LB, Pace LA, Rezaie A, Afrin LB, Molderings GJ. Mast cell activation syndrome: A primer for the gastroenterologist. Dig Dis Sci. 2021 Apr;66(4):965–82. DOI: 10.1007/s10620-020-06264-9. PMID: 32328892.
  12. Kurin M, Elangovan A, Alikhan MM, Al Dulaijan B, Silver E, Kaelber DC, et al. Irritable bowel syndrome is strongly associated with the primary and idiopathic mast cell disorders. Neurogastroenterol Motil. 2022 May;34(5):e14265. DOI: 10.1111/nmo.14265. PMID: 34535952. PMCID: PMC9191257.
  13. Valent P, Akin C, Nedoszytko B, Bonadonna P, Hartmann K, Niedoszytko M, et al. Diagnosis, classification and management of mast cell activation syndromes (MCAS) in the era of personalized medicine. Int J Mol Sci. 2020 Nov 27;21(23). DOI: 10.3390/ijms21239030. PMID: 33261124. PMCID: PMC7731385.
  14. Xi Z, Fenglin X, Yun Z, Chunrong L. Efficacy of probiotics in the treatment of allergic diseases: a meta-analysis. Front Nutr. 2025 Mar 4;12:1502390. DOI: 10.3389/fnut.2025.1502390. PMID: 40104820.
  15. Kakavas S, Karayiannis D, Mastora Z. The Complex Interplay between Immunonutrition, Mast Cells, and Histamine Signaling in COVID-19. Nutrients. 2021 Sep 29;13(10). DOI: 10.3390/nu13103458. PMID: 34684460. PMCID: PMC8537261.
  16. Hamilton MJ. Nonclonal mast cell activation syndrome: A growing body of evidence. Immunol Allergy Clin North Am. 2018 Aug;38(3):469–81. DOI: 10.1016/j.iac.2018.04.002. PMID: 30007464. PMCID: PMC6049091.
  17. Living with Mast Cell Disease – Allergy & Asthma Network [Internet]. [cited 2026 May 27]. Available from: https://allergyasthmanetwork.org/mast-cell-diseases/living-with-mcd/

Getting Started

Book your first visit

Discussion

I care about answering your questions and sharing my knowledge with you. Leave a comment or connect with me on social media asking any health question you may have and I just might incorporate it into our next listener questions podcast episode just for you!